J&J
J&J fined after ‘lying to patients for profit’
April 16, 2012Medical Communications, Sales and Marketing J&J, JJ, Janssen, Risperdal, US
A US judge has slapped a $1.19 billion fine on Johnson & Johnson after it was found to be downplaying …
J&J unveils plans to boost Doxil supplies
April 10, 2012Manufacturing and Production Ben Venue, Doxil, J&J, JJ, drug shortages
Johnson & Johnson is planning to transfer filling and packaging of Doxil to another supplier in an attempt to alleviate …
Synthes plant cited in FDA warning letter
March 8, 2012Manufacturing and Production FDA, J&J, JJ, Synthes, manufacturing
The US FDA has sent a warning letter to surgical equipment manufacturer Synthes upbraiding it for deficiencies at a manufacturing …
Alex Gorsky named new chief executive of J&J
February 22, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Janssen, Weldon
Johnson & Johnson has named Alex Gorsky as its new chief executive, effective from 26 April. Gorsky was also nominated …
J&J to pay $1 billion for Risperdal charges
January 9, 2012Sales and Marketing J&J, JJ, Janssen, Risperdal
Johnson & Johnson will pay more than $1 billion in the US to resolve a civil investigation into the marketing …
Janssen sets up new mental health social networking site
November 28, 2011Medical Communications J&J, JJ, Janssen, NHS
Janssen and the NHS Confederation have established a new mental health social networking site. The service, which will be free …
Doxil shortages exacerbated as Ben Venue shutters plant
November 22, 2011Manufacturing and Production Doxil, J&J, JJ, manufacturing and production
An acute shortage of Johnson & Johnson’s cancer drug Doxil (doxorubicin) in the US could get worse following a decision …
Xarelto succeeds in new study
November 14, 2011Sales and Marketing Bayer, FDA, J&J, JJ, Xarelto
In a new study J&J and Bayer’s blood thinner Xarelto reduced deaths in patients after a heart attack, which could …
Merck pulls out of J&J consumer venture
September 29, 2011Sales and Marketing J&J, JJ, Merc & Co, OTC
Merck & Co has exited a joint venture with J&J, selling its stake in the J&J/Merck Consumer Pharmaceuticals business to …
J&J’s latest recall put down to new factor
August 19, 2011Manufacturing and Production J&J, JJ, Tylenol, recalls
Yet another Johnson & Johnson recall has been announced, but this time the perpetrator doesn’t feature among the ‘usual suspects’. …
J&J aims for Japanese pharma expansion
May 27, 2011Research and Development, Sales and Marketing J&J, JJ
Johnson & Johnson has identified Japan as a key growth market for its pharma business as it outlines its strategic …
J&J reorganises McNeil as recalls keep coming
April 5, 2011Manufacturing and Production J&J, JJ, Johnson & Johnson, McNeil, TBA, TCA, Tylenol, manufacturing compliance, pharma manufacturing, recalls, tribromoanisole, trichloroanisole
Johnson & Johnson has announced a major reworking of its troubled McNeil Consumer Healthcare unit, just as quality problems force …
J&J charged with US manufacturing violations
March 15, 2011Manufacturing and Production J&J, JJ, Johnson and Johnson, McNeil Consumer Healthcare, McNeil Fort Washington, McNeil recall, Motrin recall, manufacturing compliance, pharma manufacturing, recalls
Johnson & Johnson subsidiary McNeil Consumer Healthcare has been officially charged with manufacturing and distributing drugs in violation of federal …
J&J hepatitis C drug begins phase III trials
February 23, 2011Research and Development J&J, JJ, Johnson and Johnson, TMC435, Tibotec, hepatitis, hepatitis C
Johnson & Johnson has begun late stage trials of hepatitis C drug TMC435 as a first line treatment for the …
Latest content
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
